Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine
PURPOSE There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete...
Main Authors: | Chyla, B. (Author), Dail, M. (Author), DiNardo, C.D (Author), Döhner, H. (Author), Fracchiolla, N.S (Author), Garcia, J.S (Author), Illes, A. (Author), Jang, J.H (Author), Jonas, B.A (Author), Ozcan, M. (Author), Potluri, J. (Author), Pratz, K.W (Author), Pullarkat, V. (Author), Recher, C. (Author), Schuh, A.C (Author), Thirman, M.J (Author), Vorobyev, V. (Author), Yamamoto, K. (Author), Yeh, S.-P (Author), Zhou, Y. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01) -
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01) -
Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01) -
Azacitidine combined with low dose Venetoclax and Azole in treatment-naive, elderly patient with acute myeloid leukemia: A case report
by: Jean Zeghondy, et al.
Published: (2020-09-01) -
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)